A patent lawsuit filed by Solos Technology against Meta Platforms, Oakley, and EssilorLuxottica targets core smart glasses technology, posing significant risks to Meta's wearables strategy and valuation.
InterDigital (NASDAQ: IDCC) has laid out an ambitious financial roadmap for fiscal year 2026, forecasting revenues up to $775 million. The outlook is supported by a newly inked licensing agreement with LG Electronics and a key smartphone renewal, signaling strong momentum in its patent portfolio.
As YouTube emerges as a key AI training data source, Reddit navigates a complex web of challenges: protecting its community brands, defending ad revenue against TikTok and AI search, and proving the value of its data licensing strategy to investors.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
NetEase Cloud Music has entered a multi-year strategic partnership with Universal Music Group, securing licensing and distribution rights for UMG's vast catalog in China. The deal aims to expand music access for Chinese listeners while creating new global promotion channels for domestic talent.
BEN finalizes a landmark AI licensing framework for Africa and a university wellbeing pilot while bolstering its balance sheet through capital raises and debt conversion, prompting analysts to question if execution is now the priority.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.
Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.
Dolby Laboratories (NYSE: DLB) kicked off fiscal 2026 with robust first-quarter results, exceeding its own revenue and earnings forecasts. The audio-visual technology leader credits strong deal timing and highlighted significant momentum in automotive, television, and mobile partnerships, including expanded ties with Qualcomm and major social media platforms.
Hawxhurst LLP has filed a federal lawsuit against International Amusement Rides and Intamin Ltd., alleging the roller coaster manufacturers failed to pay $1.5 million in legal fees after the firm defended them in high-stakes intellectual property battles.
Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.
Fidelity Investments and Broadcom have settled a legal dispute that threatened Fidelity's access to business-critical software, averting a potential operational crisis. The agreement, reached just before a key court hearing, ensures continued service for a Fidelity subsidiary.
NVIDIA's CEO Jensen Huang indicates that Chinese regulatory approval for the sale of its flagship H200 AI chip is still pending, amid high demand from major tech firms and ongoing U.S.-China tech tensions.
The Walt Disney Company has placed a $30 billion valuation on ESPN as part of its newly finalized strategic partnership with the National Football League, which includes complex future equity options and a major integration of NFL media assets.
While low-volatility stocks offer a haven during market turmoil, their defensive nature can become a liability in bull markets, potentially causing investors to miss out on significant gains. We examine three such stocks and the risks they currently pose.
Identifying companies with sustainable growth engines is a perennial challenge for investors. We analyze three firms—Vertiv, Ares Management, and Halozyme Therapeutics—that are expanding their competitive moats and delivering robust revenue growth, offering potential shelter in uncertain times.
